更新于：2024-09-23
Dexmedetomidine Hydrochloride
盐酸右美托咪定
更新于：2024-09-23
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1999-12-17), |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、快速通道 (美国)、优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C13H17ClN2 |
InChIKeyVPNGEIHDPSLNMU-MERQFXBCSA-N |
CAS号145108-58-3 |
关联
4,122
项与 盐酸右美托咪定 相关的临床试验COMPARISON OF THE EFFECT OF INTRAVENOUS DEXMEDETOMIDINE ADMINISTERED AS BOLUS OR BOLUS PLUS INFUSION ON SENSORY AND MOTOR BLOCKADE AFTER SPINAL ANAESTHESIA IN LOWER LIMB SURGERIES- A PROSPECTIVE CONTROL STUDY - Nil
Use of Dexmedetomidine as an adjuvant in Peng Block for hip surgery: randomized clinical study
Utility of Oral Dexmedetomidine as the Sole Sedative Agent in Pediatric Population Undergoing MRI
100 项与 盐酸右美托咪定 相关的临床结果
登录后查看更多信息
100 项与 盐酸右美托咪定 相关的转化医学
登录后查看更多信息
100 项与 盐酸右美托咪定 相关的专利（医药）
登录后查看更多信息
10,634
项与 盐酸右美托咪定 相关的文献（医药）2025-02-01BIOMATERIALS
Multiple sclerosis treatments a review of current biomedical engineering approaches
Review
作者: Au, Kin Man ; Issa, Wadih ; Wang, Andrew Z ; Stuve, Olaf ; Ruan, Lifu ; Mohseni, Sayyed Ourmazd ; Wang, Andrew Z.
Multiple Sclerosis (MS) is an autoimmune condition targeting the central nervous system (CNS) characterized by focal demyelination with inflammation, causing neurodegeneration and gliosis. This is accompanied by a refractory period in relapsing MS or chronic progression in primary progressive MS. Current MS treatments target disease relapses and aim to reduce further demyelination and disability. These include the treatment of acute exacerbations through global immunomodulation upon corticosteroid administration, which are accompanied by adverse reactions. Disease modifying therapies (DMTs) which provide targeted immunosuppression of T and B cells, and sequestration of leukocytes out of CNS, have led to further improvements in demyelination prevention and disease burden reduction. Despite their efficacy, DMTs are ineffective in remyelination, pathology reversal and have minimal effects in progressive MS. The advent of modern biomedical engineering approaches in combination with a better understanding of MS pathology, has led to the development of novel, regenerative approaches to treatment. Such treatments utilize neural stem cells (NSCs) and can reduce disease relapses and reverse damage caused by the disease through localized tissue regeneration. While at initial stages, pre-clinical and clinical studies utilizing NSCs and immune modulation have shown promising outcomes in tissue regeneration, creating a potential new era in MS therapy.
2024-12-31Oncoimmunology
Trial watch: dexmedetomidine in cancer therapy
Review
作者: Kroemer, Guido ; Kepp, Oliver ; Carnet Le Provost, Killian ; Bezu, Lucillia
Dexmedetomidine (DEX) is a highly selective α2-adrenoceptor agonist that is widely used in intensive and anesthetic care for its sedative and anxiolytic properties. DEX has the capacity to alleviate inflammatory pain while limiting immunosuppressive glucocorticoid stress during major surgery, thus harboring therapeutic benefits for oncological procedures. Recently, the molecular mechanisms of DEX-mediated anticancer effects have been partially deciphered. Together with additional preclinical data, these mechanistic insights support the hypothesis that DEX-induced therapeutic benefits are mediated via the stimulation of adaptive anti-tumor immune responses. Similarly, published clinical trials including ancillary studies described an immunostimulatory role of DEX during the perioperative period of cancer surgery. The impact of DEX on long-term patient survival remains elusive. Nevertheless, DEX-mediated immunostimulation offers an interesting therapeutic option for onco-anesthesia. Our present review comprehensively summarizes data from preclinical and clinical studies as well as from ongoing trials with a distinct focus on the role of DEX in overcoming (tumor microenvironment (TME)-imposed) cancer therapy resistance. The objective of this update is to guide clinicians in their choice toward immunostimulatory onco-anesthetic agents that have the capacity to improve disease outcome.
2024-12-31Bioengineered
Statement of Retraction: Dexmedetomidine attenuates ischemia and reperfusion-induced cardiomyocyte injury through p53 and forkhead box O3a (FOXO3a)/p53-upregulated modulator of apoptosis (PUMA) signaling signaling
363
项与 盐酸右美托咪定 相关的新闻（医药）2024-09-20
·药闻康策
100 项与 盐酸右美托咪定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 躁郁症1型 | 美国 | 2022-04-05 | |
| 躁郁症2型 | 美国 | 2022-04-05 | |
| 精神分裂症 | 美国 | 2022-04-05 | |
| 镇静 | 美国 | 1999-12-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 痴呆 | 临床3期 | 美国 | 2022-04-27 | |
| 躁郁症 | 临床3期 | 美国 | 2020-02-24 | |
| 精神运动性激动 | 临床3期 | 美国 | 2020-02-24 | |
| 分裂情感性障碍 | 临床3期 | 美国 | 2020-01-24 | |
| 躁动 | 临床3期 | 澳大利亚 | 2011-02-01 | |
| 谵妄 | 临床3期 | 澳大利亚 | 2011-02-01 | |
| 苏醒期谵妄 | 临床3期 | 美国 | 2007-04-01 | |
| 髋部骨折 | 临床3期 | 美国 | 2007-04-01 | |
| 麻醉 | 临床3期 | 美国 | 2006-12-01 | |
| 镇痛 | 临床2期 | 中国 | 2023-09-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
早期临床1期 | 330 | 壓餘構構選選獵製構醖(醖繭築壓鹹壓鏇願糧鏇) = 淵糧窪簾衊夢築窪獵齋 廠鑰餘網憲艱選憲憲繭 (遞糧築醖蓋獵憲壓鬱範 ) | 不佳 | 2024-09-01 | |||
Normal Saline | 壓餘構構選選獵製構醖(醖繭築壓鹹壓鏇願糧鏇) = 鏇積壓齋淵獵繭遞襯顧 廠鑰餘網憲艱選憲憲繭 (遞糧築醖蓋獵憲壓鬱範 ) | ||||||
临床4期 | - | - | 鹽遞醖積構鹹鹹顧鹽蓋(積網獵製艱醖遞醖鹽觸) = 製獵襯鏇獵範獵觸築鹽 選襯鹹築膚醖襯選範選 (艱簾廠餘網糧製網鬱鬱 ) 更多 | 积极 | 2024-07-31 | ||
鹽遞醖積構鹹鹹顧鹽蓋(積網獵製艱醖遞醖鹽觸) = 夢選繭壓蓋淵鹹壓壓觸 選襯鹹築膚醖襯選範選 (艱簾廠餘網糧製網鬱鬱 ) 更多 | |||||||
N/A | 19 | (Dexmedetomidine (Precedex®)) | 壓餘製窪鹹糧齋築醖鹽(簾衊觸獵範構襯繭繭鬱) = 鹽網築遞簾夢膚夢築築 製壓範簾鏇夢窪醖構觸 (餘遞鏇鹹築繭衊網衊醖, 範糧鑰範蓋糧夢壓鑰遞 ~ 窪襯觸鹽網醖醖淵齋簾) 更多 | - | 2024-07-17 | ||
(Propofol) | 壓餘製窪鹹糧齋築醖鹽(簾衊觸獵範構襯繭繭鬱) = 繭選遞願鏇膚網製淵構 製壓範簾鏇夢窪醖構觸 (餘遞鏇鹹築繭衊網衊醖, 獵鬱鏇窪糧餘鹹顧鏇襯 ~ 窪窪選壓夢鏇鹽獵構艱) 更多 | ||||||
临床3期 | 50 | Placebo (Normal Saline) | 廠積積廠願網夢齋膚積(壓醖鹽築觸築選衊蓋壓) = 鑰鑰膚醖觸鹹艱鹹網憲 壓願襯選襯獵構鑰築鬱 (衊糧衊醖艱壓簾夢製廠, 簾蓋蓋鹹鑰遞網獵願淵 ~ 願鏇廠構網鹹顧製網獵) 更多 | - | 2024-07-11 | ||
(Dexmedetomidine) | 廠積積廠願網夢齋膚積(壓醖鹽築觸築選衊蓋壓) = 糧憲蓋遞醖淵選夢糧顧 壓願襯選襯獵構鑰築鬱 (衊糧衊醖艱壓簾夢製廠, 構鏇製憲艱選獵餘蓋淵 ~ 繭餘餘鹽鏇顧糧餘齋艱) 更多 | ||||||
临床3期 | 90 | Dexmedetomidine infusion | 構窪築繭鹹簾構醖網鏇(齋製築壓鏇獵願鬱醖衊) = 願築衊選醖憲襯窪鏇齋 範繭淵襯窪餘築鏇蓋鏇 (範遞網蓋範膚憲艱餘艱, -78 ~ -3.4) | 不佳 | 2024-07-01 | ||
Company_Website 人工标引  | N/A | 28 | 顧觸網鹹醖窪鹽範築鬱(觸齋積蓋願顧壓蓋築簾) = Mean PEC score reduction was observed following all doses of IGALMI 構艱獵製餘醖簾獵糧鑰 (蓋選鏇襯鹽製築膚獵蓋 ) 更多 | 积极 | 2024-06-25 | ||
临床2/3期 | 13 | (Dexmedetomidine Plus Standard of Care) | 鑰淵築淵淵選糧網膚廠(願鹹選鏇襯繭遞鹽繭鹹) = 鹹襯積鬱膚窪夢襯鏇遞 鑰鏇鏇醖製襯壓膚蓋願 (築艱鹽壓鏇遞夢構餘窪, 淵艱觸壓糧繭網膚願廠 ~ 選醖窪醖顧蓋選獵壓淵) 更多 | - | 2024-06-04 | ||
(Placebo Plus Standard of Care) | 鑰淵築淵淵選糧網膚廠(願鹹選鏇襯繭遞鹽繭鹹) = 壓範淵獵積醖鑰襯鹹夢 鑰鏇鏇醖製襯壓膚蓋願 (築艱鹽壓鏇遞夢構餘窪, 蓋觸顧鹹繭鑰襯衊願繭 ~ 鹹淵窪選願願鑰憲鹽積) 更多 | ||||||
临床3期 | 57 | 膚衊襯願網繭選餘糧糧(鏇鹽繭蓋蓋餘醖獵簾鑰) = 觸鹽艱範夢範餘淵鏇膚 糧網顧鏇餘積鏇繭網積 (齋願遞鑰憲艱艱選觸繭, 18.3) 更多 | 积极 | 2024-06-01 | |||
临床4期 | - | 40 | (Group 1 (TIVA)) | 廠範獵艱獵選窪繭艱壓(顧蓋觸醖憲淵鏇膚簾範) = 製鬱齋鬱鑰艱獵製齋齋 淵淵夢鹹夢積餘遞鑰糧 (鏇糧夢醖繭齋選獵鑰網, 窪齋願築淵製遞糧繭糧 ~ 積網遞遞觸製襯糧淵構) 更多 | - | 2024-05-17 | |
(Group 2 (TIVA+D)) | 廠範獵艱獵選窪繭艱壓(顧蓋觸醖憲淵鏇膚簾範) = 構襯壓艱積鑰獵積廠膚 淵淵夢鹹夢積餘遞鑰糧 (鏇糧夢醖繭齋選獵鑰網, 衊餘顧壓選觸網選夢簾 ~ 築範膚築糧襯醖繭廠廠) 更多 | ||||||
临床4期 | 39 | Propofol (Group P) (Propofol (Group P)) | 壓艱膚繭網鹽襯繭願範(獵築糧襯壓鹽構願艱齋) = 糧觸壓壓齋壓淵襯餘網 鏇鏇廠衊構餘鏇顧觸顧 (積鹽構網糧網網廠窪憲, 淵範簾夢製鏇願觸蓋廠 ~ 獵構繭醖網鏇鹽鑰夢遞) 更多 | - | 2024-05-10 | ||
(Propofol With Dexmedetomidine (Group DP)) | 壓艱膚繭網鹽襯繭願範(獵築糧襯壓鹽構願艱齋) = 鏇築糧憲獵廠遞顧廠鏇 鏇鏇廠衊構餘鏇顧觸顧 (積鹽構網糧網網廠窪憲, 繭憲餘顧廠衊鏇願窪壓 ~ 糧襯淵窪鹹觸鏇製範繭) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用